Encorafenib is a Small Molecule owned by Pfizer, and is involved in 56 clinical trials, of which 15 were completed, 39 are ongoing, and 2 are planned.

Encorafenib is an B-Raf kinase inhibitor with antineoplastic activity. LGX818 specifically inhibits B-Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway results in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.

The revenue for Encorafenib is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Encorafenib NPV Report.

Encorafenib was originated by Novartis and is currently owned by Pfizer. Ono Pharmaceutical is the other company associated in development or marketing of Encorafenib.

Encorafenib Overview

Encorafenib (Braftovi) acts as anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Braftovi is indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test and treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation.

Encorafenib (LGX-818) is under development for the treatment of melanoma and non-small cell lung cancer, metastatic thyroid cancerar, advanced BRAF mutant metastatic colorectal cancer and metastatic BRAF (gene) mutant melanoma, refractory and relapsed multiple myeloma. It was also under development for the treatment of non-small cell lung cancer, thyroid cancer, brain metastases and hematological malignancies.

Ono Pharmaceutical Overview

Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY361,361 million for the fiscal year ended March 2022 (FY2022), an increase of 16.8% over FY2021. In FY2022, the company’s operating margin was 28.6%, compared to an operating margin of 31.8% in FY2021. In FY2022, the company recorded a net margin of 22.3%, compared to a net margin of 24.4% in FY2021. The company reported revenues of JPY109,979 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Encorafenib

Report Segments
  • Innovator (NME)
Drug Name
  • Encorafenib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.